In this interview we discuss long-term data on the anti–PD-L1 immunotherapy atezolizumab in metastatic triple-negative breast cancer.
In this interview we discuss the use of CTCs and circulating tumor DNA for prognosis and disease monitoring in patients with breast cancer.
No one can accurately predict what will happen with the ACA, but that doesn't mean physicians can't chart a path forward.
In this podcast, the chief innovation officer at the UPMC health system joins us to explain the potential of artificial intelligence in reducing burnout.
In this interview we discuss the idea behind an enhanced recovery program for patients undergoing cytoreductive surgery for ovarian cancer, as well as some of the potential cost savings.
In this interview we discuss the approach to treating cancer in lesbian, gay, bisexual, transgender, and queer (LGBTQ) patients.
In this interview we discuss the latest therapy developments in the treatment of multiple myeloma.
In this interview we discuss clinical developments in essential thrombocythemia, polycythemia vera, and myelofibrosis, as well as the latest treatment options.
Facing something like the Zika epidemic is challenging for any healthcare organization, but especially when they lack significant resources.
In this interview we discuss a new study that looked at the outcomes of patients with small renal masses who were followed with active surveillance.